386 related articles for article (PubMed ID: 22333687)
21. Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications.
Wang K; Fan DD; Jin S; Xing NZ; Niu YN
Asian J Androl; 2014; 16(2):274-9. PubMed ID: 24457841
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory effects of isoflavonoids on rat prostate testosterone 5α-reductase.
Bae M; Woo M; Kusuma IW; Arung ET; Yang CH; Kim YU
J Acupunct Meridian Stud; 2012 Dec; 5(6):319-22. PubMed ID: 23265084
[TBL] [Abstract][Full Text] [Related]
23. 5α-reductase type 3 enzyme in benign and malignant prostate.
Titus MA; Li Y; Kozyreva OG; Maher V; Godoy A; Smith GJ; Mohler JL
Prostate; 2014 Feb; 74(3):235-49. PubMed ID: 24150795
[TBL] [Abstract][Full Text] [Related]
24. Development of a quantitative RT-PCR method to study 5alpha-reductase mRNA isozymes in rat prostate in different androgen status.
Torres JM; Ruiz E; Ortega E
Prostate; 2003 Jun; 56(1):74-9. PubMed ID: 12746849
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
26. Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1.
Issa S; Schnabel D; Feix M; Wolf L; Schaefer HE; Russell DW; Schweikert HU
J Clin Endocrinol Metab; 2002 Dec; 87(12):5401-7. PubMed ID: 12466325
[TBL] [Abstract][Full Text] [Related]
27. Serenoa repens extracts: In vitro study of the 5α-reductase activity in a co-culture model for Benign Prostatic Hyperplasia.
Buonocore D; Verri M; Cattaneo L; Arnica S; Ghitti M; Dossena M
Arch Ital Urol Androl; 2018 Sep; 90(3):199-202. PubMed ID: 30362688
[TBL] [Abstract][Full Text] [Related]
28. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
Traish AM
Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
[TBL] [Abstract][Full Text] [Related]
29. The role of dihydrotestosterone in benign prostatic hyperplasia.
Carson C; Rittmaster R
Urology; 2003 Apr; 61(4 Suppl 1):2-7. PubMed ID: 12657354
[TBL] [Abstract][Full Text] [Related]
30. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
Marberger M
Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
[TBL] [Abstract][Full Text] [Related]
31. Targeting 5α-reductase for prostate cancer prevention and treatment.
Nacusi LP; Tindall DJ
Nat Rev Urol; 2011 May; 8(7):378-84. PubMed ID: 21629218
[TBL] [Abstract][Full Text] [Related]
32. Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders.
Paba S; Frau R; Godar SC; Devoto P; Marrosu F; Bortolato M
Curr Pharm Des; 2011; 17(2):151-67. PubMed ID: 21361868
[TBL] [Abstract][Full Text] [Related]
33. [Expression and significance of steroid 5alpha-reductase isoenzymes in benign hyperplastic prostate tissues].
Ye LF; Zhang YF; Fang ZJ; Ding Q; Yao MS
Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(15):1296-9. PubMed ID: 12930680
[TBL] [Abstract][Full Text] [Related]
34. [Dutasteride in the treatment of benign prostatic hyperplasia: an update].
Chen HJ; Chen YR
Zhonghua Nan Ke Xue; 2011 Jan; 17(1):63-7. PubMed ID: 21351536
[TBL] [Abstract][Full Text] [Related]
35. [5alpha-dihydrotestosterone (DHT)].
Komiya A; Suzuki H; Ichikawa T
Nihon Rinsho; 2005 Aug; 63 Suppl 8():452-6. PubMed ID: 16149549
[No Abstract] [Full Text] [Related]
36. Exploration of Novel 5α-Reductase Inhibitors for Benign Prostatic Hyperplasia by 2D/3D QSAR, Cytotoxicity Pre-ADME and Docking Studies.
Dhingra R; Malhotra M; Sharma V; Bhardwaj TR; Dhingra N
Curr Top Med Chem; 2018; 18(32):2816-2834. PubMed ID: 30659542
[TBL] [Abstract][Full Text] [Related]
37. Self organizing molecular field analysis on a series of human 5alpha-reductase inhibitors: unsaturated 3-carboxysteroid.
Thareja S; Aggarwal S; Bhardwaj TR; Kumar M
Eur J Med Chem; 2009 Dec; 44(12):4920-5. PubMed ID: 19716209
[TBL] [Abstract][Full Text] [Related]
38. Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases.
Salvador JA; Pinto RM; Silvestre SM
J Steroid Biochem Mol Biol; 2013 Sep; 137():199-222. PubMed ID: 23688836
[TBL] [Abstract][Full Text] [Related]
39. Expression of steroid 5α-reductase isozymes in prostate of adult rats after environmental stress.
Sánchez P; Torres JM; Castro B; Olmo A; del Moral RG; Ortega E
FEBS J; 2013 Jan; 280(1):93-101. PubMed ID: 23122426
[TBL] [Abstract][Full Text] [Related]
40. Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases.
Cabeza M; Sánchez-Márquez A; Garrido M; Silva A; Bratoeff E
Curr Med Chem; 2016; 23(8):792-815. PubMed ID: 26861003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
